双HER2靶向双特异性抗体Zanidatamab治疗不可切除局部晚期或转移性HER2阳性唾液腺癌患者的早期研究合并分析

Purpose: Human epidermal growth factor receptor 2 (HER2) overexpression occurs in various subtypes of salivary gland cancers (SGC) and can be associated with treatment challenges and poor clinical outcomes. Zanidatamab is a dual HER2-targeted, bispecific antibody that has demonstrated antitumor activity across multiple HER2-positive tumor types. This combined analysis aimed to assess the efficacy and safety of zanidatamab in HER2-positive SGC. Patients and methods: Adult patients with previously treated, unresectable locally advanced or metastatic HER2-positive SGC were enrolled in three early-phase trials of zanidatamab: a first-in-human phase I study (NCT02892123), a phase I study of patients in Japan (JRCT2031210161), and a phase Ib/II study evaluating zanidatamab plus evorpacept, a high-affinity CD47 inhibitor (NCT05027139). Confirmed objective response rate (cORR) and progression-free survival (PFS) were measured in each study. Outcomes with zanidatamab monotherapy were pooled for summary analysis. Results: Ten patients with HER2-positive SGC were enrolled across trials; six patients were previously treated with HER2-targeted therapy. Among patients who received zanidatamab monotherapy (n = 9), seven experienced zanidatamab-related adverse events (all grade 1/2), the most common being diarrhea and infusion-related reactions. The cORR [95% confidence interval (CI)] was 44% (14%-79%), the median (95% CI) PFS was 10.1 (3.8-not estimable) months, and the median (range) duration of response was not reached (9.4 to 42.3+ months). All patients experienced a reduction in tumor size. One patient who received zanidatamab plus evorpacept experienced a confirmed partial response and 18.4 months of PFS. Conclusions: Although the sample size is small, these findings support the clinical benefit of zanidatamab treatment for HER2-positive SGC.